Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Awad

Showing results (771-780 of 839) with videos related to

Pageof 84
Sort By:
JAMA Oncology|May 22, 2025
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung CancerBiagio Ricciuti, Francesca Fusco, Alissa Cooper, et al.
Cancer Research|September 8, 2022
Genomic Landscapes and Hallmarks of Mutant RAS in Human CancersRobert B Scharpf, Archana Balan, Biagio Ricciuti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 20, 2025
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small-cell lung cancerB Ricciuti, S Scalera, X Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 4, 2025
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLCSeshiru Nakazawa, Federica Pecci, Biagio Ricciuti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 17, 2021
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapyA Cortellini, B Ricciuti, F Facchinetti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2018
Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non-Small Cell Lung CancerMagda Bahcall, Mark M Awad, Lynette M Sholl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancersJ K Sabari, G C Leonardi, C A Shu, et al.
Science (New York, N.Y.)|November 15, 2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancerAdam S Crystal, Alice T Shaw, Lecia V Sequist, et al.
International Journal of Radiation Oncology, Biology, Physics|September 7, 2016
The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain MetastasesPaul W Sperduto, T Jonathan Yang, Kathryn Beal, et al.
Circulation. Heart Failure|May 14, 2025
Detection of Hypertrophic Cardiomyopathy on Electrocardiogram Using Artificial IntelligenceJames M Hillis, Bernardo C Bizzo, Sarah F Mercaldo, et al.
Pageof 84

Showing results (771-780 of 839) with videos related to

Sort By:
Pageof 84
JAMA Oncology|May 22, 2025
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung CancerBiagio Ricciuti, Francesca Fusco, Alissa Cooper, et al.
Cancer Research|September 8, 2022
Genomic Landscapes and Hallmarks of Mutant RAS in Human CancersRobert B Scharpf, Archana Balan, Biagio Ricciuti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 20, 2025
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small-cell lung cancerB Ricciuti, S Scalera, X Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 4, 2025
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLCSeshiru Nakazawa, Federica Pecci, Biagio Ricciuti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 17, 2021
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapyA Cortellini, B Ricciuti, F Facchinetti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2018
Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non-Small Cell Lung CancerMagda Bahcall, Mark M Awad, Lynette M Sholl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancersJ K Sabari, G C Leonardi, C A Shu, et al.
Science (New York, N.Y.)|November 15, 2014
Patient-derived models of acquired resistance can identify effective drug combinations for cancerAdam S Crystal, Alice T Shaw, Lecia V Sequist, et al.
International Journal of Radiation Oncology, Biology, Physics|September 7, 2016
The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain MetastasesPaul W Sperduto, T Jonathan Yang, Kathryn Beal, et al.
Circulation. Heart Failure|May 14, 2025
Detection of Hypertrophic Cardiomyopathy on Electrocardiogram Using Artificial IntelligenceJames M Hillis, Bernardo C Bizzo, Sarah F Mercaldo, et al.
Pageof 84